ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

BCL2

BCL2 apoptosis regulator · also Bcl-2, PPP1R50 · Protein phosphatase 1 regulatory subunits

7 programs in company-led studies act on BCL2, from 4 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
venetoclaxruleAbbVieinhibitorphase 48325 running–ChEMBL
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalinhibitorphase 385 running–the company's pipeline
lacutoclaxruleLupeng Pharmaceuticalinhibitorphase 243 running–the studies' text
surzetoclaxAbbVie–phase 233 running–the company's pipeline
400mg of TQB3909 tabletsSino Biopharmaceuticalinhibitorphase 210 running–the company's pipeline
surzetoclaxAbbVie–phase 122 running–the company's pipeline
FXS0683Fosun Pharma–phase 111 running–the company's pipeline

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.